CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1M, lower than 95% of all stocks globally
- PositionOperating margin is -5570.5%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
609.20MUSDvs all stocks (USD)
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.10xvs all stocks
52-Week Change
174.45%vs all stocks
Market Capitalization
609.20MUSDvs all stocks (USD)
Enterprise Value
403.58MUSDvs all stocks (USD)
Forward P/E
-11.57xvs Biotechnology peers
Price to Book (MRQ)
2.90xvs Biotechnology peers
Enterprise to Revenue
403.58xvs Biotechnology peers
Enterprise to EBITDA
-7.74xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-24.43%vs Biotechnology peers
Return on Equity (TTM)
-39.21%vs Biotechnology peers
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0100USDUpdated Sep 28, 2026Gross Profit (TTM)
-38.24MUSDvs all stocks (USD)
EBITDA (TTM)
-52.14MUSDvs all stocks (USD)
Net Income (TTM)
-52.57MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-41.03MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.22MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.00MUSDFY2025 · Dec 31, 2025Operating Income
-51.51MUSDvs all stocks (USD)
Pre-tax Income
-48.81MUSDFY2025 · Dec 31, 2025Net Income
-48.81MUSDFY2025 · Dec 31, 2025EBIT
-51.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.82MUSDFY2025 · Dec 31, 2025Research & Development
35.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.70MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-48.81MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-39.89MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.96MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-48.81MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.69MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-599.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-318.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-843.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-71.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-43.42MUSDFY2025 · Dec 31, 2025Sale of Investments
35.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
-65.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
44.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
100.73MSharesUpdated Sep 28, 2026Float Shares
67.76MSharesUpdated Sep 28, 2026Shares Short
6.81MSharesUpdated Sep 28, 2026Short Ratio
8.70daysvs all stocks
Short % of Shares Outstanding
7.03%vs all stocks
% Held by Insiders
4.08%vs all stocks
% Held by Institutions
80.14%vs all stocks
Total Cash (MRQ)
208.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.08USDUpdated Sep 28, 2026Total Debt (MRQ)
2.67MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0127xvs Biotechnology peers
Current Ratio (MRQ)
27.59xvs Biotechnology peers
Book Value per Share (MRQ)
2.10USDUpdated Sep 28, 2026Total Assets
91.03MUSDvs all stocks (USD)
Total Current Assets
82.47MUSDFY2025 · Dec 31, 2025Total Liabilities
8.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.55MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.19MUSDFY2025 · Dec 31, 2025Other Short-term Investments
23.87MUSDFY2025 · Dec 31, 2025Accounts Payable
2.10MUSDFY2025 · Dec 31, 2025Short-term Debt
837.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
236.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-430.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
82.39MUSDvs all stocks (USD)
52-Week Low
1.70USDUpdated Sep 28, 202652-Week High
8.33USDUpdated Sep 28, 202652-Week Change
174.45%vs all stocks
Beta
1.10xvs all stocks
50-Day MA
6.97USDUpdated Sep 28, 2026200-Day MA
5.75USDUpdated Sep 28, 2026Avg 10-Day Volume
1.67MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.07MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.4400USDUpdated Sep 28, 2026Other Income / Expense
-4.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5570.5%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -55.70Industry median: -0.38Industry P5: -43.63Peers compared: 260
Current ratio is 27.59×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 27.59Industry median: 5.71Industry P95: 22.21Peers compared: 260
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,000,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Wuyang Automation Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Apogee Optocom Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Novoprotein Scientific Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity